专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20190192998A1 Vessel and Method for Solid-Liquid Separation 审中-公开
公开(公告)号：US20190192998A1
公开(公告)日：2019-06-27
申请号：US15852674
申请日：2017-12-22
申请人： Larry Baxter , David Frankman , Skyler Chamberlain , Kyler Stitt , Christopher Hoeger , Eric Mansfield , Andrew Baxter , Nathan Davis
发明人： Larry Baxter , David Frankman , Skyler Chamberlain , Kyler Stitt , Christopher Hoeger , Eric Mansfield , Andrew Baxter , Nathan Davis
IPC分类号： B01D21/00 , B01D21/02 , B01D21/24 , B01D17/02 , F25J3/08
CPC分类号： B01D21/009 , B01D17/0214 , B01D21/0024 , B01D21/10 , B01D21/2405 , F25J3/08 , F25J2205/02 , F25J2205/20 , F25J2220/66
摘要： Devices, systems, and methods for separating solids from liquids are disclosed. A vessel includes an inlet, a carrier liquid outlet, a product outlet, a purifying section, and a heater. The inlet directs a slurry into the purifying section. The slurry comprises particles of a solid and a carrier liquid. The purifying section preferentially drives the particles of the solid towards a heating zone of the purifying section versus the carrier liquid. This displaces a first portion of the carrier liquid away from the heating zone of the purifying section. The heater heats the slurry. The carrier liquid outlet drives a majority of the carrier liquid out of the vessel. The product outlet is adjacent to the heating zone of the purifying section.

2. 发明申请

US20180266761A1 Self-Cleaning Desublimating Heat Exchanger for Gas/Vapor Separation 审中-公开
公开(公告)号：US20180266761A1
公开(公告)日：2018-09-20
申请号：US15464250
申请日：2017-03-20
申请人： Larry Baxter , Skyler Chamberlain , Eric Mansfield , Andrew Baxter , Nathan Davis
发明人： Larry Baxter , Skyler Chamberlain , Eric Mansfield , Andrew Baxter , Nathan Davis
IPC分类号： F25J3/08
CPC分类号： F25J3/061 , B01D5/0003 , B01D8/00 , B01D53/002 , B01D2257/504 , B01D2258/0283 , F25J3/0625 , F25J3/067 , F25J5/002 , F25J2205/20 , F25J2210/70 , F25J2290/44 , F28D7/06 , F28D7/1623 , F28F17/00 , F28F19/01 , F28G7/00
摘要： A heat exchanger for separating a vapor component from a carrier gas is disclosed. The carrier gas is cooled in an outer chamber, causing a vapor component of the carrier gas to desublimate or condense onto an outer surface of an inner chamber, forming a solid product. A coolant is passed through the inner chamber to cool the carrier gas of the outer chamber. A means for causing the inner chamber to flex is provided, causing the solid product to fall from the outer surface of the inner chamber for collection. In this manner, the vapor component is separated from the carrier gas.

3. 发明申请

US20100143566A1 Frozen Aerated Confections and Methods for Producing Them 有权
标题翻译：冷冻加气混合物及其生产方法
公开(公告)号：US20100143566A1
公开(公告)日：2010-06-10
申请号：US12632246
申请日：2009-12-07
申请人： Florence Clotilde Cagnol , Andrew Richard Cox , Andrew Baxter Russell
发明人： Florence Clotilde Cagnol , Andrew Richard Cox , Andrew Baxter Russell
IPC分类号： A23G3/52 , A23G3/46
CPC分类号： A23G9/46 , A23G9/38
摘要： A frozen aerated confection is provided, the confection comprising at least 0.2 wt % free β-casein, wherein the free β-casein constitutes more than 45% of the total β-casein present in the frozen confection; and containing a population of gas bubbles, wherein at least 65% of the gas bubbles have a diameter of less than 20 μm. A process for producing such a frozen aerated confection is also provided.
摘要翻译：提供了一种冷冻充气甜食，糖果包含至少0.2重量％的游离＆amp;酪蛋白，其中游离蛋白酪蛋白构成存在于冷冻甜食中的总皂苷的45％以上; 并且含有一群气泡，其中至少65％的气泡具有小于20μm的直径。还提供了一种生产这种冷冻充气甜食的方法。

4. 发明申请

US20070185036A1 Ester derivatives of rhein and their therapeutic use 失效
标题翻译：大黄酸的酯衍生物及其治疗用途
公开(公告)号：US20070185036A1
公开(公告)日：2007-08-09
申请号：US10591157
申请日：2005-03-04
申请人： Andrew Baxter , Andrea Walmsey
发明人： Andrew Baxter , Andrea Walmsey
IPC分类号： A61K38/00
CPC分类号： C07C66/02
摘要： Compounds that may have anti-inflammatory activity are of general formula (I); wherein X1, is H or COR1, and X2 is H or COR2 but X1, and X2 are not both H; R1 and R2 are the same or different and are each C1-4 alkyl substituted with R3, or a four to seven-membered ring which can be optionally substituted with R8 and can contain one or more additional heteroatoms selected from O, S(O)n and NR9; is R3 is F, CF3, OR4, NR5R6 O, S(O)n R7; R4, R5 and R6 are the same or different and are each H or C1-4 alkyl optionally substituted with R3, or NR5R6 is a C4-6 heterocycloalkyl ring containing one or more heteroatoms selected from O, NR8 and S(O)n; each n is 0-2; R7 is C1-4 alkyl; R8 is as defined for R3 or C1-4 alkyl optionally substituted with R3 or halogen; and R9 is H or C1-4 alkyl; or a salt, solvate or hydrate thereof.
摘要翻译：可具有抗炎活性的化合物具有通式（I）; 其中X 1是H或COR 1，并且X 2是H或COR 2，但X _{1 且X 2不同时为H; R 1和R 2各自相同或不同，并且各自是被R 3 3取代的C 1-4烷基，，或可以任选被R 8'取代的4-7元环，并且可以含有一个或多个选自O，S（O）n N和NR的另外的杂原子 9 R 3是F，CF 3或OR 4，NR 5 R 6，或 > O，S（O）n R 7 R 7; R 4，R 5和R 6相同或不同，各自为H或C 1-4烷基，任选被R 3 3或NR 5 R 6取代的烷基是含有一个的C 4-6 - 杂环烷基环或更多选自O，NR 8和S（O）n的杂原子。每个n为0-2; R 7是C 1-4烷基; R 8如R 3或C 1-4烷基所定义，任选被R 3或卤素取代; 并且R 9是H或C 1-4烷基; 或其盐，溶剂合物或水合物。}

5. 发明申请

US20060235016A1 Morpholine Dopamine Agonists 失效
标题翻译：吗啉多巴胺激动剂
公开(公告)号：US20060235016A1
公开(公告)日：2006-10-19
申请号：US11425030
申请日：2006-06-19
申请人： Charlotte Allerton , Andrew Baxter , Andrew Cook , David Hepworth , Stephen Wong
发明人： Charlotte Allerton , Andrew Baxter , Andrew Cook , David Hepworth , Stephen Wong
IPC分类号： A61K31/5377 , C07D413/04
CPC分类号： C07D265/30 , C07D413/04
摘要： The present invention provides for compounds of formula (I), (Ia) and (Ib) Wherein: A is selected from C—X and N, B is selected from C—Y and N, R1 is selected from H and (C1-C6)alkyl, R2 is selected from H and (C1-C6)alkyl, X is selected from H, HO, C(O)NH2, NH2 Y is selected from H, HO, NH2, Br, Cl and F Z is selected from H, HO F, CONH2 and CN; And pharmaceutically acceptable salts, solvates and prodrugs thereof; With the provisos that: for a compound of formula (I), (Ia) or (Ib), when A is C—X, B is C—Y, R1 is H or (C1-C6)alkyl and R2 is H or (C1-C6)alkyl at least one of X, Y and Z must be OH; for a compound of formula (I), when A is C—X and B is C—Y, Y is H, Z is H, R1 is H and R2 is H, then X cannot be OH; these compounds are useful as a medicament.
摘要翻译：本发明提供式（I），（Ia）和（Ib）的化合物，其中A选自CX和N，B选自CY和N，R 1选自H 和（C 1 -C 6 -C 6）烷基，R 2选自H和（C 1 -C 6烷基） C 1 -C 6烷基，X选自H，HO，C（O）NH 2，NH 2 Y选自H，HO， NH 2，Br，Cl和FZ选自H，HOF，CONH 2和CN; 其药学上可接受的盐，溶剂合物和前药; 条件是：对于式（I），（Ia）或（Ib）的化合物，当A为CX时，B为CY，R 1为H或（C 1 < C 1 -C 6烷基，R 2是H或（C 1 -C 6 -C 6）烷基， X，Y和Z中的至少一个必须是OH; 对于式（I）化合物，当A为CX且B为CY时，Y为H，Z为H，R 1为H且R 2为H，那么X不能是OH; 这些化合物可用作药物。

6. 发明申请

US20060111573A1 Resolution of mefloquine with o,o-di-p-aroyltartaric acid 审中-公开
标题翻译：用o，邻二芳基酒石酸分解甲氟喹
公开(公告)号：US20060111573A1
公开(公告)日：2006-05-25
申请号：US10531128
申请日：2003-12-04
申请人： Andrew Baxter , Michael Harris , Stuart Brown
发明人： Andrew Baxter , Michael Harris , Stuart Brown
IPC分类号： C07D401/02
CPC分类号： C07D401/06
摘要： A process for increasing the optical purity of a mixture of enantiomers of mefloquine, used a substantially single entantiomer of a O,O-di-p-aroyltartaric acid as a resolving agent.
摘要翻译：用于提高甲氟喹对映异构体混合物的光学纯度的方法，使用作为拆分剂的O，O-二对芳基酒石酸的基本上单一的对映异构体。

7. 发明申请

US20060052435A1 Selective dopamin d3 receptor agonists for the treatment of sexual dysfunction 审中-公开
标题翻译：选择性多巴胺d3受体激动剂治疗性功能障碍
公开(公告)号：US20060052435A1
公开(公告)日：2006-03-09
申请号：US10499210
申请日：2002-12-10
申请人： Pieter Van der Graaf , Christopher Peter Wayman , Andrew Baxter , Andrew Cook , Stephen Wong
发明人： Pieter Van der Graaf , Christopher Peter Wayman , Andrew Baxter , Andrew Cook , Stephen Wong
IPC分类号： A61K31/405
CPC分类号： A61K31/5375 , A61K31/00 , A61K45/06
摘要： The use of a composition comprising a selective dopamine D3 receptor agonist, wherein said dopamine D3 receptor agonist is at least about 15-times more functionally selective for a dopamine D3 receptor as compared with a dopamine D2 receptor when measured using the same functional assay, in the preparation of a medicament for the treatment and/or prevention of sexual dysfunction.
摘要翻译：使用包含选择性多巴胺D3受体激动剂的组合物，其中所述多巴胺D3受体激动剂对于多巴胺D3受体的功能选择性与多巴胺D2受体相比，当使用相同的功能测定法测定时，其功能选择性为至少约15倍，制备用于治疗和/或预防性功能障碍的药物。

8. 发明申请

US20060025423A1 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases 失效
标题翻译： N-吡嗪基 - 苯基磺酰胺及其在治疗趋化因子介导的疾病中的应用
公开(公告)号：US20060025423A1
公开(公告)日：2006-02-02
申请号：US10501510
申请日：2003-01-14
申请人： Andrew Baxter , Timothy Johnson , Nicholas Kindon , Bryan Roberts , Michael Stocks
发明人： Andrew Baxter , Timothy Johnson , Nicholas Kindon , Bryan Roberts , Michael Stocks
IPC分类号： A61K31/4965 , C07D241/02
CPC分类号： C07D231/12 , C07D233/56 , C07D241/22 , C07D249/08 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07F7/0812
摘要： The invention provides N-pyrazinyl-phenyl-sulphonamides of formula (I) for use in the treatment of chemokine mediated diseases. Particularly inflammatory diseases, such as asthma.
摘要翻译：本发明提供了用于治疗趋化因子介导的疾病的式（I）的N-吡嗪基 - 苯基 - 磺酰胺。特别是炎性疾病，如哮喘。

9. 发明授权

US06903085B1 Substituted piperidine compounds useful as modulators of chemokine receptor activity 失效
标题翻译：可用作趋化因子受体活性调节剂的取代哌啶化合物
公开(公告)号：US06903085B1
公开(公告)日：2005-06-07
申请号：US10069215
申请日：2000-08-18
申请人： Stephen Thom , Andrew Baxter , Nicholas Kindor , Thomas McInally , Brian Springthorpe , Matthew Perry , David Harden , Richard Evans , David Marriott
发明人： Stephen Thom , Andrew Baxter , Nicholas Kindor , Thomas McInally , Brian Springthorpe , Matthew Perry , David Harden , Richard Evans , David Marriott
IPC分类号： C07D473/34 , A61K31/4468 , A61K31/4525 , A61K31/453 , A61K31/4535 , A61K31/454 , A61K31/4545 , A61K31/46 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/519 , A61K31/52 , A61P1/00 , A61P1/04 , A61P3/10 , A61P9/10 , A61P11/00 , A61P11/02 , A61P11/06 , A61P17/00 , A61P17/06 , A61P17/14 , A61P19/00 , A61P19/02 , A61P19/08 , A61P25/00 , A61P25/06 , A61P29/00 , A61P37/00 , A61P37/06 , A61P43/00 , C07D211/58 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D451/04 , C07D487/04 , C07D491/056 , C07D495/04 , C07D513/04 , A61K31/33 , A61K31/435 , A61K31/445 , C07D211/00 , C07D413/00
CPC分类号： C07D401/12 , C07D211/58 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
摘要： The invention provides compounds of formula (I) wherein R1, R2, R3, R6, Z, Q, m, n, X1, X2, X3, X4 and T are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy, especially for the treatment of chemokine receptor related diseases and conditions
摘要翻译：本发明提供式（I）化合物，其中R 1，R 2，R 3，R 6， Z，Q，m，n，X 1，X 2，X 3，X 4和T分别为如本说明书中所定义的，其制备方法，含有它们的药物组合物及其在治疗中的用途，特别是用于治疗趋化因子受体相关疾病和病症

10. 发明授权

US06303659B2 Compounds 失效
公开(公告)号：US06303659B2
公开(公告)日：2001-10-16
申请号：US09745740
申请日：2000-12-26
申请人： Andrew Baxter , Thomas McInally , Michael Mortimore , David Cladingboel
发明人： Andrew Baxter , Thomas McInally , Michael Mortimore , David Cladingboel
IPC分类号： A61K31166
CPC分类号： C07D203/14 , C07C233/65 , C07C235/46 , C07C235/60 , C07C237/30 , C07C323/62 , C07C2603/74 , C07D209/08 , C07D213/82 , C07D233/64 , C07D295/13
摘要： The invention provides adamantane derivatives, a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式